Third Harmonic Bio Announces Third Quarter 2023 Financial Results (GlobeNewswire) - Nov 9, 2023 - "Third Harmonic Bio, Inc...today announced financial results for the third quarter ended September 30, 2023...With IND-enabling studies continuing to progress, the company is on track to file a U.S. IND and initiate a Phase 1 SAD/14-day MAD study of THB335 to evaluate safety, pharmacokinetics and pharmacodynamics during the first half of 2024...Research and development (R&D) expenses increased to $6.0 million for the three months ended September 30, 2023, from $4.8 million for the same period in 2022....The increases were primarily due to increases in discovery and development and personnel-related costs relating to the research and nonclinical development of THB335 and other next-generation discovery efforts."
Commercial • IND • New P1 trial • Dermatology • Immunology • Urticaria
|